Squarepoint
CAPR icon

Squarepoint’s Capricor Therapeutics CAPR Stock Holding History

Squarepoint’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,600
Closed -$146K – 4646
2024
Q4 		$146K Buy
+10,600
New +$186K ﹤0.01% 4579

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Squarepoint's CAPR Position: Q1 2026 in Review

Squarepoint opened a new position in Capricor Therapeutics (CAPR) in Q1 2026: 12,500 shares worth $380K. The stake represents ﹤0.01% of the portfolio and ranks #3528 among its holdings. This is a return to the name: Squarepoint previously reported a position in CAPR as recently as Q2 2025.

Squarepoint first reported a position in CAPR in Q2 2024 and has held it in 5 quarters since. The position peaked at $1.62M in Q1 2025. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • Squarepoint held 12,500 shares of Capricor Therapeutics worth $380K as of Q1 2026.
  • Capricor Therapeutics was a new Squarepoint position in Q1 2026.
  • Capricor Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3528 holding.
  • Squarepoint first reported a position in Capricor Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • Squarepoint's Capricor Therapeutics position peaked at $1.62M in Q1 2025.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.